Trial record 1 of 6 for:    ELND005
Previous Study | Return to List | Next Study

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

This study has been terminated.
Elan Pharmaceuticals
Information provided by (Responsible Party):
Transition Therapeutics Ireland Limited Identifier:
First received: January 8, 2013
Last updated: September 9, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)